The increased cardiovascular risk and dyslipidemia in HIV-infected individuals is difficult to treat for several reasons. Statins reduce LDL-C levels less in HIV-infected individuals compared to uninfected controls. Fibrates reduce triglyceride levels less in HIV-infected individuals compared to uninfected controls as well. Drug-drug interactions between statins and protease inhibitors increase the risk of adverse events. Due to these interactions, simvastatin and lovastatin are contraindicated among individuals receiving protease inhibitors and the dose of atorvastatin should not exceed 40 mg. Even interactions with rosuvastatin, which is not metabolized by the cytochrome P450 system, have been described.